(Q33396036)

26 July 2017

Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study (English)

1 reference

26 July 2017

1 reference

G S Nowakowski

1

1 reference

26 July 2017

B LaPlant

2

1 reference

26 July 2017

T M Habermann

3

1 reference

26 July 2017

C E Rivera

4

1 reference

26 July 2017

W R Macon

5

1 reference

26 July 2017

D J Inwards

6

1 reference

26 July 2017

I N Micallef

7

1 reference

26 July 2017

P B Johnston

8

1 reference

26 July 2017

L F Porrata

9

1 reference

26 July 2017

S M Ansell

10

1 reference

26 July 2017

R R Klebig

11

1 reference

26 July 2017

C B Reeder

12

1 reference

26 July 2017

T E Witzig

13

1 reference

26 July 2017

language of work or name

1 reference

1 July 2011

1 reference

26 July 2017

1 reference

26 July 2017

25

1 reference

26 July 2017

12

1 reference

26 July 2017

1877-1881

1 reference

https://scigraph.springernature.com/pub.10.1038/leu.2011.165

26 July 2017

0 references

cites work

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.165

Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.165

Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.165

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.165

Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.165

Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.165

Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.165

Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.165

Rituximab-lenalidomide-dexamethasone induces complete and durable remission in relapsed refractory diffuse large B-cell non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.165

Thalidomide and a thalidomide analogue drug costimulate virus-specific CD8+ T cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.165

Circulating endothelial progenitor cells in multiple myeloma: implications and significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.165

Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.165

Revised response criteria for malignant lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.165

Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.165

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.165

The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.165

lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.165

2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.165

Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.165

Thrombotic complications in adult patients with lymphoma: a meta-analysis of 29 independent cohorts including 18 018 patients and 1149 events

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.165

Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.165

Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.165

MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.165

7 January 2021

Randomized comparison of MACOP-B with CHOP in patients with intermediate-grade non-Hodgkin's lymphoma. The Australian and New Zealand Lymphoma Group

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.165

7 January 2021

MACOP-B versus ProMACE-MOPP in the treatment of advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.165

7 January 2021

An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.165

7 January 2021

Lenalidomide and venous thrombosis in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.165

7 January 2021

Identifiers

DOI

10.1038/LEU.2011.165

1 reference

Dimensions Publication ID

26 July 2017

0 references

1 reference